GLP-1 Medications and Menopause: Can They Help With Midlife Weight Gain?

The weight gain that arrives in perimenopause is different from weight gained at other points in life. Women who describe it use specific language: it lands in a different place (predominantly around the abdomen), it resists the usual interventions, and it arrives without any clear change in diet or exercise habits. This is not imagination. It reflects a genuine shift in metabolic biology driven by declining oestrogen.

GLP-1 medications are increasingly being considered by women in this demographic, both alongside HRT and as an alternative when HRT is not suitable. The evidence base is not as specific to menopausal women as it could be, but it is growing, and the mechanistic rationale is compelling.

Here is what we know.

What Menopause Does to Body Composition

The metabolic changes of perimenopause begin years before the final menstrual period, driven primarily by declining and increasingly erratic oestrogen levels. The consequences for body composition are specific and substantial.

Visceral fat accumulation. Oestrogen plays an important role in directing fat storage away from the abdomen and towards the hips, thighs, and gluteal region (the so-called gynoid distribution). As oestrogen falls, fat redistribution towards the abdomen accelerates. Visceral fat (the metabolically active fat surrounding the abdominal organs) increases by approximately 12% across the menopausal transition, independently of total weight gain.

Reduced resting metabolic rate. Muscle mass declines with age and accelerates with oestrogen loss. Since muscle is metabolically expensive tissue, this reduces total daily energy expenditure. The caloric equation that maintained weight at 35 no longer balances at 50.

Worsening insulin sensitivity. Oestrogen has insulin-sensitising effects. Its decline is associated with meaningful worsening of insulin resistance, increasing fat storage propensity and making weight loss harder.

Sleep disruption. Hot flushes and night sweats impair sleep quality, increasing cortisol and appetite-stimulating hormones (particularly ghrelin), and reducing the satiety hormone leptin.

The cumulative effect: women gain weight during the menopausal transition without necessarily eating more or moving less. The cause is metabolic, not behavioural.

How GLP-1 Medications Interact With Menopausal Biology

GLP-1 receptor agonists work on appetite regulation, gastric emptying, and insulin secretion via the GLP-1 pathway (and additionally via GIP in the case of tirzepatide). These mechanisms are relevant to menopausal weight gain regardless of the hormonal context.

Several features of GLP-1 medications are particularly relevant to perimenopausal women:

Visceral fat reduction. GLP-1 medications produce preferential reductions in visceral fat relative to subcutaneous fat. In clinical trials, even modest overall weight loss on GLP-1 medications is associated with disproportionate reduction in waist circumference and visceral adiposity. This is precisely the fat compartment that accumulates most during menopause and that carries the greatest metabolic and cardiovascular risk.

Insulin sensitisation. GLP-1 medications improve insulin sensitivity both directly and through weight loss, counteracting the insulin resistance that worsens with oestrogen decline.

Appetite regulation. The reduction in food noise and appetite that GLP-1 medications produce may be particularly valuable in menopausal women, where sleep disruption and cortisol changes drive appetite dysregulation.

The Clinical Evidence in Menopausal Women

The major GLP-1 trials (STEP 1 for semaglutide, SURMOUNT-1 for tirzepatide) enrolled mixed populations and were not specifically powered to examine menopausal subgroups. Subgroup analyses exist but have limitations in sample size.

The TREAT trial examined semaglutide in women with type 2 diabetes and included a substantial postmenopausal subgroup:

The consistent message from subgroup analyses: GLP-1 medications work in menopausal women. The hormonal environment of menopause does not appear to blunt the efficacy of these medications meaningfully.

What is not yet well-characterised in dedicated trials is the interaction between GLP-1 medications and HRT, specifically whether the combination produces synergistic effects on visceral fat, insulin resistance, or cardiovascular risk markers beyond either treatment alone.

HRT and GLP-1: Complementary, Not Competing

This is, in my view, the most important clinical concept for perimenopausal women considering GLP-1 medications.

HRT and GLP-1 medications address different aspects of the menopausal metabolic problem:

HRT addresses the hormonal deficiency. It reduces hot flushes and night sweats, improves sleep quality, helps maintain bone density, reduces the rate of visceral fat accumulation driven by oestrogen loss, and improves insulin sensitivity through direct hormonal mechanisms. It does not suppress appetite or produce significant weight loss.

GLP-1 medications address appetite dysregulation, insulin resistance, and active weight and fat loss. They do not replace oestrogen or address the hormonal deficiency of menopause directly.

Used together, they target different mechanisms. There is no pharmacological interaction that makes the combination unsafe; they work via entirely different pathways. Some preliminary observational data suggests the combination may produce greater improvements in visceral adiposity and insulin sensitivity than either alone, though this has not yet been examined in a dedicated trial.

Muscle Loss: A Particular Concern for Older Women

Muscle loss on GLP-1 medications is a concern for any user, but the risk is meaningfully higher in women over 45. The combination of menopausal muscle loss, the muscle-preserving effect of oestrogen declining, and the calorie restriction that comes with GLP-1-induced appetite suppression creates a genuine risk of sarcopenic change during weight loss treatment.

Studies suggest that 25 to 40% of weight lost on GLP-1 medications may be lean mass rather than fat, though this varies considerably based on protein intake and physical activity.

Mitigation strategies for menopausal women:

• Prioritise resistance training: at minimum 2 to 3 sessions per week targeting major muscle groups
• Protein intake: aim for 1.6 to 2.0 g per kg of body weight daily, which will require deliberate effort on a reduced appetite
• Adequate leucine intake: ensures protein synthesis is triggered (eggs, dairy, meat, legumes in sufficient quantity)
• Consider slower dose escalation to allow food intake to adjust less abruptly

For the full evidence and protocol on preserving muscle during GLP-1 treatment, see muscle loss prevention on GLP-1 for women. See also the guide on protein intake on GLP-1 for practical advice on hitting targets on a reduced appetite.

Sleep, Cortisol, and GLP-1

Hot flushes and night sweats fragment sleep. Poor sleep drives up cortisol and ghrelin (appetite-stimulating), while reducing leptin (satiety-promoting). This creates a bidirectional relationship between menopausal sleep disruption and weight gain that compounds over time.

GLP-1 medications can help with the weight component of this cycle. But they do not directly address the root cause of sleep disruption, which is hormonal. Women whose sleep quality is significantly impaired by menopausal symptoms will typically see greater benefit from addressing those symptoms directly (via HRT, or non-hormonal alternatives like SSRIs or the newer neurokinin B antagonists) alongside GLP-1 treatment, rather than relying on GLP-1 medications alone.

Baseline Testing Before Starting

Before starting a GLP-1 medication in a perimenopausal or postmenopausal context, a comprehensive baseline test helps to contextualise results and identify any contraindications. Key components include:

• FSH, LH, oestradiol (to assess menopausal status if not yet confirmed)
• Fasting glucose, HbA1c, fasting insulin
• Full lipid profile
• Thyroid function
• Liver and renal function
• Full blood count including ferritin and vitamin D

For a full guide to pre-treatment blood testing for GLP-1 medications, see what blood tests to do before starting GLP-1.

NHS Access for Menopausal Women Seeking GLP-1

NHS access to Wegovy for obesity follows standard NICE TA875 criteria: BMI 35+ with a weight-related condition, or BMI 40+, via specialist weight management services. Menopausal status is not itself a criterion. Women in perimenopause who meet BMI criteria are eligible in the same way as any adult.

The waiting lists in most areas are significant. See NHS Wegovy eligibility 2026 for realistic current timelines and what to do while waiting.

For women accessing GLP-1 treatment privately, specialist menopause and women's health clinics that offer GLP-1 prescribing are beginning to emerge. The combination of menopause specialist oversight and GLP-1 prescribing in one service is the ideal setup for this population.

What to Expect: Realistic Outcomes

For perimenopausal and postmenopausal women on GLP-1 medications, based on the available subgroup data:

• Weight loss is consistent with the broader population: approximately 15% of body weight with semaglutide, approximately 20-22% with tirzepatide at full doses
• Visceral fat reduction may be proportionally greater than overall fat loss, addressing the specific menopausal pattern
• Insulin resistance improvement is significant and rapid
• Muscle loss risk is higher than in younger women and requires deliberate protein and exercise strategies
• Efficacy is not meaningfully blunted by menopausal status itself

The metabolic improvements from GLP-1 treatment (reduced visceral fat, better insulin sensitivity, improved lipid profile) are cardiovascular risk reductions that matter considerably more at 50+ than at 30.

For women considering which medication to start with, the full Mounjaro vs Wegovy for women comparison covers efficacy, cost, and NHS access in detail.